Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
MacroGenics, a U.S.-based antibody therapeutics developer, and Servier, a French pharmaceutical company, have entered an agreement to develop and commercialize therapies aimed at three undisclosed tumor targets. They will use MacroGenics’ dual-affinity retargeting (DART) antibody platform. DART proteins can be used to redirect the body’s cell-destroying immune effector cells against tumors. MacroGenics will receive a $20 million up-front payment and retain full development and commercialization rights to the three preclinical DART programs in North America and Asia.
This article has been sent to the following recipient: